Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 141 No. 1112 (2011)

Hepatitis delta in Switzerland: a silent epidemic

  • I Rossi
DOI
https://doi.org/10.4414/smw.2011.13176
Cite this as:
Swiss Med Wkly. 2011;141:w13176
Published
14.03.2011

Summary

OBJECTIVES:The sero-prevalence of co-infection with the hepatitis B virus (HBV) and the hepatitis D virus (HDV) is well known in many European countries, starting from 6.8% in Germany to more than 27% in some Turkish areas. To gain a better description of this infection in Switzerland, and to characterise those affected, a questionnaire was sent to all Swiss gastroenterologists, hepatologists and infectologists.

METHODS:A questionnaire was received by 349 physicians which asked them to report on all HBV- and HDV-infected patients seen at their units/offices.

RESULTS:A total of 101 HDV-positive patients seen by 78 specialists were analysed. The physicians were in charge of 1’699 patients with chronic hepatitis B, giving a 5.9% prevalence of HDV infection in HBV-positive patients. A predominance of males (75%) from Switzerland (39%), and of African origin (21%) was recorded. Most had been contaminated by intravenous drug use (62%), followed by vertical transmission (15%), sexual contact (13%) or transfusion with blood or blood products (2%). The majority (74%) had a very low (<103 UI/ml) HBV viral load and 75% were HBeAg-negative. A total of 76% percent of those who had a liver biopsy had significant fibrosis (≥F2), and only 21% had received standard therapy (interferon or pegylated interferon-α). Overall, 10% recovered spontaneously (anti-HBs-positive).

CONCLUSION:With a prevalence of 5.9% of hepatitis D in HBsAg-positive patients, Switzerland seems less affected than most other European countries, however, it is possible that this infection is under-diagnosed. Intravenous drug use was the main risk factor. Associated advanced liver disease was also very common.

References

  1. Rizzetto M, Canese MG, Arico S, Crivelli O, Bonino F, Trepo CG, et al. Immunofluorescence detection of a new antigen/antibody system (delta/anti-delta) associated with hepatitis B virus in liver and serum of HBsAg carriers. Gut. 1977;18:997–1003.
  2. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian C, Thayer G, et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature. 1986;323:508–14.
  3. Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: Overview. Prog Clin Biol Res. 1991;364:1.
  4. Hadziyannis SJ. Review: Hepatitis delta. J Gastroenterol Hepatol. 1997;12(4):289–98.
  5. Colombo P, et al. Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. J Hepatol. 1991;12:64–9.
  6. Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet. 1987;1:478–82.
  7. Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Déni P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005;43:2363–9.
  8. Grabowski J, Wedemeyer H. Hepatitis Delta: Immunopathogenesis and clinical challenges. Dig Dis. 2010;28:133–8.
  9. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–7.
  10. Degertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;4:494–8.
  11. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in central Europe. J Viral Hepat. 2009;16:883–94.
  12. Frösner GG, Franco E, Altorfer J, Decker RH, Mushahwar IK. Prevalence of Antibody to delta hepatitis virus population groups in west Germany and Switzerland. Eur J Clin Microbiol. 1985;4;147–9.
  13. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe. Hepatology. 2007;45:1331–2.
  14. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.
  15. Sheng W, Hung C, Kao J, Chang S, Chen M, Hsieh S, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active anti-retroviral therapy: a matched cohort study. Clin Infect Dis. 2007;44:988–95.
  16. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–7.
  17. Calle Serrano B, Heidrich B, Jaroszewicz J, Deterding K, Raupach R, Cornberg M, et al. Long-term outcome of hepatitis delta: A 14-year single center experience. Hepatology. 2009;50:737A.